对PEG-b-PLA/Eudragit S100混合物的研究,研究蓝色卡明染料的纳米封装和控制释放中的应用
Shaked Ashkenazi1, Pnina Matsanov1, Eid Nassar-Marjiya2
1Department of Biotechnology Engineering, Braude College of Engineering Karmiel, Karmiel 2161002, Israel.
ACS omega
|March 25, 2024
概括
这项研究探讨了混合聚合物,如聚乙烯糖醇-块-聚-乳酸和Eudragit S100如何影响纳米囊中的红色卡明封装. 最佳的混合物增强着染料的积累,并使生物医学用途的控制释放成为可能.
科学领域:
- 聚合物科学 聚合物科学
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 聚合物纳米囊正在研究药物输送和封装.
- 聚乙烯甘醇-块-聚乳酸 (PEG-b-PLA) 和Eudragit S100是纳米载体系统中的关键聚合物.
- 红色卡明 (IC) 是一种离子染料,具有潜在的生物医学应用.
研究的目的:
- 为了研究PEG-b-PLA/Eudragit S100混合比在调整红色卡明封装中的作用.
- 了解聚合物混合的可混合性和表面电荷如何影响纳米囊的特性.
- 为了优化纳米囊配方,以控制有机染料的释放.
主要方法:
- 制备PEG-b-PLA和Eudragit S100在不同比例 (100/0,90/10,75/25,50/50% w/w) 的二元聚合物混合物.
- 在纳米囊核心中封装蓝色卡明 (IC).
- 分析聚合物混合物的可混合性,热稳定性和表面电荷.
- 从纳米囊中评估IC释放配置文件.
主要成果:
- 增加Eudragit S100含量降低了聚合物混合物的混合性,但增强了热稳定性.
- 含有10%和25%Eudragit S100的配方显示出最佳的负表面电荷和可混合性.
- 阳离子Eudragit S100促进了纳米囊核心内的IC积累和自我组装.
- 混合改善了IC释放,实现了缓慢和受控的释放动力学.
结论:
- PEG-b-PLA与Eudragit S100的比例显著影响纳米囊的特性和染料封装.
- 优化的聚合物混合物促进了高效的印花卡明加载和受控释放.
- 这些发现支持用于涉及有机染料的生物医学应用的聚合物纳米系统的合理设计.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
310
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
310
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
91
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
91
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
106
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
106
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
114
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
114
01:11Oral Drug Delivery Systems: Delayed-Release Systems
153
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
153